Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigmine.
The muscarinic antagonist scopolamine and the benzodiazepine lorazepam both produce transient impairments in memory and attention in normal volunteers. These impairments can be reversed by appropriate agents such as the cholinesterase inhibitor physostigmine in the case of scopolamine or the benzodiazepine antagonist Ro 15-1788 in the case of lorazepam. In this paper we investigated the pharmacological specificity of these reversals by examining the interactions of scopolamine and Ro 15-1788 and of lorazepam and physostigmine. There was no evidence that the effects of scopolamine and lorazepam on cognitive function could be attenuated by Ro 15-1788 and physostigmine, respectively. The results are discussed in terms of pharmacological models of Alzheimer's disease.
Preston
G C
GC
Neuroscience Research Centre, Merck, Sharp & Dohme, Essex, UK.
Ward
C
C
Lines
C R
CR
Poppleton
P
P
Haigh
J R
JR
Traub
M
M
D000161:Acoustic Stimulation; D000328:Adult; D014151:Anti-Anxiety Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D001288:Attention / Q000187:drug effects; D003072:Cognition Disorders / Q000139:chemically induced / Q000523:psychology; D003704:Dementia / Q000139:chemically induced* / Q000523:psychology; D004195:Disease Models, Animal; D005260:Female; D005442:Flumazenil / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000139:chemically induced / Q000523:psychology; D010775:Photic Stimulation; D010830:Physostigmine / Q000494:pharmacology*; D011597:Psychomotor Performance / Q000187:drug effects; D011680:Pupil / Q000187:drug effects; D011930:Reaction Time / Q000187:drug effects; D012601:Scopolamine / Q000037:antagonists & inhibitors / Q000494:pharmacology*
D014151:Anti-Anxiety Agents; D005442:Flumazenil; D010830:Physostigmine; D012601:Scopolamine